Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
NAB Q3 Cash Earnings Rise 2% as Lower Credit Charges Boost Profit 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Add as a preferred source on Google
AstraZeneca has discontinued a late-stage clinical trial evaluating volrustomig combined with chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC), dealing another setback to the pharmaceutical giant’s drug development pipeline.
The company said Monday that it stopped the Phase III eVOLVE-Lung02 trial following a recommendation from an independent data monitoring committee. The committee concluded that the volrustomig combination was unlikely to achieve the study’s primary endpoints of improving progression-free survival (PFS) or overall survival (OS).
The trial focused on patients whose tumors lacked PD-L1 expression and compared the experimental treatment with the study’s control arm.
Despite the disappointing efficacy findings, AstraZeneca reported no unexpected safety issues. The safety profile observed with volrustomig and chemotherapy remained consistent with the known profiles of the individual treatments, with no new safety concerns identified.
Susan Galbraith, AstraZeneca’s executive vice president of oncology hematology research and development, acknowledged the disappointing outcome while emphasizing that the company intends to apply lessons from the study to its ongoing efforts to develop new lung cancer treatments.
eVOLVE-Lung02 was a large global study involving 895 patients across 25 countries, highlighting the scale of AstraZeneca’s investment in testing volrustomig as a potential treatment for metastatic NSCLC.
The trial discontinuation adds to investor scrutiny of the AstraZeneca drug pipeline following several clinical setbacks this year. The company is pursuing an ambitious target of reaching $80 billion in annual revenue, making the performance of its late-stage pipeline increasingly important to its long-term growth strategy.
Another notable setback involved Wainua, developed with Ionis Pharmaceuticals. Earlier this year, results from the Phase III CARDIO-TTRansform study showed that the treatment failed to outperform placebo in reducing cardiovascular deaths among patients with a progressive and potentially fatal heart condition.
The latest failure underscores the uncertainty surrounding late-stage pharmaceutical development, even as AstraZeneca continues investing heavily in oncology, cardiovascular disease and rare-disease therapies.
